jiliko slot

The didgeridoo is a wind instrument made by hollowing out the limbs or even the trunks of trees. It produces a low-pitched, soulful, resonant hum. This alone makes it captivating enough but the indigenous Australian people believe this long, wooden flute, which may perhaps be the oldest instrument known to mankind, connects them to the invisible forces that shape our world. It certainly felt like it on the morning of the first Border-Gavaskar Trophy Test. Perth Stadium - whose walls are adorned with 17 verses of indigenous Noongar prose - practically shook in tune with the music. When all this was happening, had found himself a little spot over on the other side of the ground and was taking some last-minute throwdowns, except it went way longer than that and if it hadn't been time for the national anthems, he might have kept going. "This is the toughest challenge," had said leading up to the game. "So I give this message to everyone: if you come and perform in this country then your cricket level will go up." "This is where you make your name for yourself on one of the biggest stages in the world to play cricket," bowling coach had said. "I think that's one of the driving forces in this group of young guys to come up here and play good, solid cricket, score five-, six-hundred runs in a series, take 19-20 wickets, and put yourself on that stage. It's a fantastic carrot to dangle in front of Indian players." certainly took this whole opening-the-batting business really seriously, but he seemed equally preoccupied with something else as well during the first half-hour of play. Gardening. He kicked the dirt off his batting crease. He marked and re-marked his guard. He patted the grass by the side of the pitch. He patted the good-length area of the pitch. He wanted to stay connected with the game. He wanted to stay plugged in. He wanted to get in that zone. On Friday, at Perth Stadium, if you weren't in the zone, you didn't exist. **** Bumrah was among the first to be back out there at the change of innings. And he was letting them fly. His genius has distorted reality before and just then it seemed like he was fine working with 150 on the board. It can be the dark that makes his light shine brighter. The pace was up. At the pre-match press conference, he picked up on the words "medium-fast" and forgot about everything else that followed including the next one - "allrounder". The question was actually about , but he fired back "150 , fast bowler " [I bowl 150kph, call me a fast bowler please]. Misplaced indignation aside, there's a chance he's underselling himself there. Bumrah created four wicket-taking opportunities with his first 12 deliveries on tour. He was doing almost the same thing in the nets, but there were no stakes there. Nathan McSweeney was the only casualty during this period of play, out lbw to a good-length ball curved into his front pad. He could have been dismissed earlier when a back-of-a-length ball zipped past his outside edge. Marnus Labuschagne's score - 2 off 52 - could easily have lost its curiosity value if Virat Kohli had been able to take a catch that he offered from the second ball he faced. This one was angled in and held its line. Bumrah was bowling fast - yeah, so fast bowler makes sense - but he brings people alive. A record crowd for a Test match day in Perth - 31,302 - including a very quiet Indian contingent until their captain was on a hat-trick. Then they began chanting his name. He makes the batting crease - which is usually wide open space - claustrophobic. He has his own gravity. Everybody at the ground was drawn to him when he was at the top of his mark. He makes his own rules. Pitches aren't 22 yards long when he's bowling. It's about time cricket finds something else to describe him. Mitchell Starc pretty much said there's nobody like him: "He's obviously got a fair bit of hyperextension in that elbow and does things a lot of actions won't let you do. So there's no surprise he's been a fantastic bowler across formats for a long time and again his skills were on show today as to how good he is. I'm sure there's something in that release point that's significant to his action. It's something that a lot of people can't do. I'm certainly not going to go and try it." **** India's batters did the best they could. The score at lunch - 51 for 4 - and immediately afterwards, when Mitchell Marsh was taking wickets - 73 for 6 - may not have looked nice but they were facing a relentless bowling attack that was able to generate, on average, 0.8 degrees of seam movement. That's a lot. Three of the four Tests played at Perth Stadium before this one offered much less in terms of deviation after pitching: 0.65, 0.56, 0.62. India matched their hosts with the ball. They too were able to gain 0.8 degrees of seam on average, and , playing only his 11th first-class match, got almost twice that (1.36 degrees) when he dismantled Travis Head. The whole team got around him, which was good because he looked like he was ready to run straight out of the stadium. To be 22 years old and able to conjure that kind of magic on debut. Rana and Reddy were both told on match eve that they would be playing. Twenty-four hours later, both of them have played a significant part in India turning their fortunes around in about as dramatic a manner as there could be. "We got to know just before one day," Reddy said after the day's play. "We were a little excited as well. Obviously nervousness as well was there. We were having dinner and we were just keeping ourselves the way we were last week. We wanted to continue that. We wanted to take no pressure. So we had a cycle ride as well last evening and it was good." Australia were expecting to face a very different bowling attack. They practiced hard for left-arm spin. Ravindra Jadeja got on the pitch only at lunch, to do some running drills. They have had enough run-ins with R Ashwin to be wary of him no matter the conditions. He was at the indoor nets, experimenting with legspin. They thought at least one of them would play. So did almost everybody else. India went in with a team designed to give them depth. An uncapped batting allrounder at No. 8. An uncapped bowling allrounder at No. 9. Washington Sundar, he of the no-look six from three years ago, as the lone spinner, a senior fast bowler who hasn't had a good time of late, and him. The biggest him in the world of cricket right now.jiliko slot 。

None

San Francisco 49ers quarterback Brock Purdy will miss Sunday's game against the Packers with a sore throwing shoulderNEW YORK , Dec. 12, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global biologics contract development and manufacturing organization (CDMO) market size is estimated to grow by USD 10.63 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.46% during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards advent of big data. However, capacity utilization and constraints poses a challenge. Key market players include 3P BIOPHARMACEUTICALS S.L.U, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, particularly in the areas of small molecules and large molecules, including biologics, biosimilars, cancer therapies, monoclonal antibodies, and vaccines. This trend is driven by the increasing demand for specialized expertise and advanced technology in the production of complex biological medicinal products. Niche CDMOs and biopharmaceutical CDMOs are leading the way in the production of biologics, such as recombinant proteins and monoclonal antibodies, using cutting-edge technology like advanced manufacturing technologies, single-use/disposable bioreactors, and automation. The focus on infectious diseases, chronic diseases, and novel therapies, such as immunotherapy, is also driving growth in the market. The disease landscape is constantly evolving, with an increasing focus on evidence-based practice and the development of treatments for conditions like diabetes, geriatric population, and metabolic illnesses. Supply chain management, quality testing, and third-party logistic providers are essential components of the CDMO market, ensuring the production of high-quality biological medications and vaccinations. The use of advanced technology, such as software development and process engineering, is crucial for the production of complex biological molecules, including nucleic acids, cell receptors, and post-translational changes. Pharma clients require CDMOs to provide clinical services, from fermentation and tissue processing to cell bank creation and cell line engineering. The production of biological medications and vaccinations requires a deep understanding of biology, as well as expertise in areas like myelosuppression, cardiotoxicity, renal insufficiency, and neurotoxicity. The CDMO market is expected to continue growing, with a focus on the production of small-molecule drugs, biopharmaceuticals, and biological medications, as well as the development of novel therapies for diseases like allergies, gene therapy, and metabolic syndrome. The use of advanced technology, specialized expertise, and niche CDMOs will be key to meeting the demands of the market and delivering high-quality products to patients. The pharmaceutical industry's technological advancements extend beyond drug research and development to data analytics. This tool is increasingly utilized for clinical data synthesis, expediting the drug development process. Big data is a popular strategy in healthcare, including pharmaceuticals, for informed research and development decisions. Data analytics effectively identifies potential new drug candidates, creates simulation models to assess drug efficacy, pinpoints patient populations through various sources, and monitors potential side effects for early avoidance. Biologics Contract Development and Manufacturing Organizations (CDMOs) leverage these analytics to streamline their services, ensuring efficient and effective drug development. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! Market Challenges The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth due to the increasing demand for biologics, biosimilars, and novel therapies in various disease areas. However, this market faces challenges in producing both small molecules and large molecules, including biologics, monoclonal antibodies, and vaccines. The supply chain for these complex products requires advanced technology, specialized expertise, and collaboration with third-party logistic providers. Biologics CDMOs focus on biological medicinal products, such as recombinant proteins, monoclonal antibodies, and vaccines. They face challenges in producing these products using fermentation, microbial fermentation, and advanced manufacturing technologies, such as single-use/disposable bioreactors. Niche CDMOs specialize in areas like cancer therapies, infectious diseases, and rare diseases, requiring evidence-based practice and cutting-edge technology. The disease landscape includes chronic infectious diseases, ageing, and multisystem functional decline, affecting geriatric populations. These conditions require careful consideration of myelosuppression, cardiotoxicity, renal insufficiency, neurotoxicity, polypharmacy, and mental state. Biopharmaceutical CDMOs must ensure quality testing, automation, software development, process engineering, and biology expertise to meet the needs of pharma clients. The Biologics segment includes monoclonal antibodies, immunotherapy, and gene therapy, requiring tissue processing, cell bank creation, and cell line engineering. Novel therapies, such as nucleic acids, cell receptors, and metabolic illnesses, add complexity to the production process. The challenges of producing these biological molecules and managing their supply chain necessitate collaboration between CDMOs, pharma clients, and other stakeholders. The biologics Contract Development and Manufacturing Organization (CDMO) market is currently challenged by capacity utilization issues. Capacity utilization refers to the ratio of actual production to the potential production when a company's capacity is fully utilized. This measure plays a significant role in manufacturing various therapeutics, particularly biological drugs, due to the intricate production process. Approximately 35% of CDMOs encounter minor capacity utilization constraints during manufacturing, while 20% experience moderate to major constraints. These manufacturing constraints hinder CDMOs from reaching their full production potential, leading to delays in the release of numerous therapeutics. Insights into how AI is reshaping industries and driving growth- Download a Sample Report Segment Overview This biologics contract development and manufacturing organization (cdmo) market report extensively covers market segmentation by 1.1 Mammalian 1.2 Microbial 2.1 Biologics 2.2 Biosimilars 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Mammalian- The mammalian segment holds a significant share in the global biologics Contract Development and Manufacturing Organization (CDMO) market due to the increasing use of mammalian cells in producing therapeutic proteins for various diseases. Mammalian cells, derived from mammalian tissue, are primarily used for growing animal cells in vitro, and there are four main types: fibroblasts, epithelial cells, lymphocytes, and macrophages. Lymphocytes are found in the blood, while the others are found in tissue. Mammalian cell culture is widely used for producing human proteins with high therapeutic potential, such as tissue plasminogen activators, clotting factors, and erythropoietin, which cannot be produced using bacteria or yeasts. Recombinant proteins from mammalian cells are used in therapeutics for conditions like diabetes and cancer. Additionally, mammalian cell culture technology is utilized for bulk vaccine production, contributing to market growth. For instance, Catalent Inc. Signed an agreement in June 2020 to develop a COVID-19 vaccine using its GPEx cell line development technology. Catalent offers comprehensive services, including mammalian cell line development, process development, process validation, formulation development, and drug substance manufacturing, from preclinical to commercial stages. These factors are expected to drive the growth of the mammalian segment in the global biologics CDMO market. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) Research Analysis The Biologics Contract Development and Manufacturing Organization (CDMO) market caters to the production of Biological Medicinal Products, including large molecules such as monoclonal antibodies, biosimilars, cancer therapies, and small molecules. These CDMOs play a crucial role in supplying the pharma industry with high-quality products, serving clients in various therapeutic areas like chronic infectious diseases and diabetes. Advanced manufacturing technologies, like single-use/disposable bioreactors, automation, and software development, are transforming the industry. Smaller, niche BioCDMOs also thrive, offering specialized services in areas like tissue processing and clinical services. The focus on quality testing ensures the production of safe and effective biological medicines, meeting regulatory requirements. Biopharmaceutical companies benefit from the expertise and capabilities of these CDMOs, streamlining their supply chain and accelerating time-to-market for new treatments. Market Research Overview The Biologics Contract Development and Manufacturing Organization (CDMO) market encompasses the production of biologics, including small molecules, large molecules, biosimilars, monoclonal antibodies, cancer therapies, and various specialized therapies such as vaccines, recombinant proteins, and novel therapies. This market caters to the supply chain needs of pharmaceutical clients, focusing on quality testing, third-party logistic providers, and advanced technology. Biologics CDMOs offer specialized expertise in areas like fermentation, microbial fermentation, and advanced manufacturing technologies, including single-use/disposable bioreactors. The market landscape includes a range of niche and biopharmaceutical CDMOs, serving various disease areas like infectious diseases, chronic diseases, and cancer. Cutting-edge technology and evidence-based practice are integral to the biologics CDMO sector, which includes the production of biological medicinal products, small-molecule drugs, and biopharmaceuticals. The biology of cells, tissue processing, cell bank creation, cell line engineering, and post-translational changes are crucial aspects of biologics production. The geriatric population, with ageing and multisystem functional decline, presents unique challenges, including myelosuppression, cardiotoxicity, renal insufficiency, neurotoxicity, polypharmacy, and mental state. Biologics CDMOs address these challenges through automation, software development, process engineering, and biology expertise. The biologics CDMO sector also covers the production of vaccinations, somatic cells, tissues, and various biological molecules, including nucleic acids, cell receptors, and metabolic illnesses like diabetes. Allergy treatments, gene therapy, and therapies for various diseases like cancer, infectious diseases, and metabolic syndrome are also part of the biologics CDMO market. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Type Mammalian Microbial Product Type Biologics Biosimilars Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE TechnavioUniversity Of Utah's Course On Cannabis And Feminism Explores Assumptions Around Marijuana And More

Khalid is opening up about his sexuality. In a series of posts on X, the "Young Dumb & Broke" singer came out as gay. He revealed the news on X by a rainbow flag with exclamation points in a post that read, "There yall go. next topic please lol." He then responded to a fan who asked if he was "GEHHH," , "I am! And that’s okay." In a follow up message, Khalid, whose birth name is Khalid Donnel Robinson, said he outed by someone but did not share who the person was. TODAY.com has reached out to the Grammy-nominated singer for comment but did not hear back at the time of publication. "I got outted and the world still continues to turn. Let’s get this straight (lmao) I am not ashamed of my sexuality!" . "In reality it ain’t nobodies business! But I am okay with me love yall." After sharing the news, the singer continued to interact with fans online about it. "The closet was glass baby. but we accept you. its not about who you love its about your artistry!" a to which "I wasn’t hiding anything! It’s just not any of your business." Online, someone pointed out that Khalid likely teased his sexuality when he released his 2022 song "Satellite," which is known as a “LGBTQ anthem." "Hate that Khalid was forced out but he wasn’t “hiding” it. He just didn’t need to TELL nobody," , "Thank you!!!! I was never hiding." After a slew of interactions with fans following his announcement, Khalid signaled he was signing off of X , "Aight love yall thank yall I’m off this." Khalid broke out onto the scene in 2016 when he released his hit song "Location," which featured artists like Lil Wayne and Kehlani on the remix. The singer has been nominated for seven Grammys, including Joyann Jeffrey is a trending news reporter based in New York City

MELBOURNE, Australia (AP) — Australia's House of Representatives passes bill banning children younger than age 16 from social media.

Greek Prime Minister Kyriakos Mitsotakis participated in the 3rd Greek Investment Conference in London, held by Morgan Stanley and the Athens Stock Exchange on Monday, and held a discussion with Morgan Stanley Vice-President Luigi Rizzo. At his introductory statement at the event, Mitsotakis spoke of the progress of the Greek economy, which still lagged behind other countries of similar size (Ireland, Portugal). He attributed that to what he called the political world's "inability to formulate the required consensus for practical steps to modernize the country, (and) the fact that we obviously suffered needlessly during the crisis due to political choices made." The PM expressed the certainty that Greece will be able to make up the lost ground and become a truly European country, leading in sectors where it has "an inherent comparative advantage." As an example of resistance to change before its implementation he gave the newly inaugurated Thessaloniki Metro, "an image of Greece's future, a trajectory we shall remain fully focused on." Mitsotakis said it was important to win the support for change not just of the investment community and large companies, but of the majority of the Greek public, which will reap the benefits of the growth. Workshop with Blair, Hassabis PM Mitsotakis outlined the priorities Greece had in the coming years, which he explained: retaining fiscal stability and meeting obligations; using this stable fiscal foundation to continue focusing on productive investments, whether domestic or foreign; and managing skills and technology, while ensuring Greece is at the forefront of artificial intelligence (AI). On the latter, he said he participated in a three-hour workshop with former UK Prime Minister Tony Blair and Nobel prize winner Demis Hassabis, CEO and cofounder of Google DeepMind, to better understand how to use AI to improve government policies. He also mentioned health services, noting that "health care is, on a social front, my number one priority. I believe that we are now pioneers in seeing health not just through the aspect of therapy of a disease, but through prevention. The prevention policies implemented in Greece today, in terms of preliminary checks, are truly pioneering. There are not that many European countries doing what we are doing." Mitsotakis denied there will be an extra tax on bank profits, spoke of Greece's efforts to reduce polluting emissions, and underlined the importance of balancing green transition without destroying industry. "I believe the number one priority for the European Commission is to examine how it will reduce the energy cost for industries and consumers. There are ways we can work toward this direction," he underlined. He also spoke of climate change and its destruction, protecting water resources, and prioritizing the protection of human lives above all during extreme weather. Regional unrest, migration Speaking of the regional instability, including Ukraine, the Middle East and Syria in particular, and the upcoming Trump government, the premier said that Greece hoped to play a role of stability and influence in developments. The future could bring new opportunities, such as contributing to Ukraine's rebuilding, and connecting with India, a country that offers Greece the greatest opportunities. In addition, Mitsotakis reiterated the need for Europe to build its own defense and build its own defense industry. Referring to the migration issue, he said that human traffickers should be at the core of a policy, supported by returns of migrants who do not qualify for asylum. "Returns are something that has not been achieved yet. Those whose asylum applications are rejected end up staying in Europe in one way or another, and this is a great problem," the Greek PM said. "This must be a European project. We must leverage European funds. We cannot have, for example, favorable regulations with countries and not use the leverage we have to tell them they have to accept returns." Europe also needs a better and more ambitious agenda on legal migration and working visas, with countries like Egypt, India, and the Philippines, as Greece is doing. AI and ethics On AI, Mitsotakis said Greece had just published its strategy for AI compiled by a lsit of Greek specialists and AI from Greece and abroad. What Greece can offer is a large number of AI specialists and innovators abroad who would want to get involved with what is happening back in Greece, where there is an emerging ecosystem of AI tartup businesses and state support, including a digital transformation ministry. "We are claiming one of seven 'AI factories' positions" as a country, the Greek premier said, adding that Greece is building its first Greek supercomputer and has issued tenders that will give it access to key European funding for AI. "I believe that from the aspect of a milder policy - but again a very important one, given our heritage - should be to become leaders in the space that bridges ethics and AI. We have this additional advantage that we can become the central focus point for such discussions, which are unbelievably interesting, not just at intellectual level, but will one day lead to regulations in terms of protecting us from the negative aspects of AI," PM Mitsotakis underlined.

IIM Mumbai Concludes First Phase Of 2025 Placements; Microsoft Offers Top Package Of ₹54 LPA

Andrew P. Strada’s Dec. 1 column (” A Trump voter’s modest proposal for moving ahead without rancor or finger-pointing ”) reasonably calls for calm in spite of political differences. Strada sounds like one with whom I could have a cordial discussion in spite of my being a centrist Democrat. However, he lost me in his failure to mention extreme GOP rhetoric while lamenting ”hyperbolic ad hominem attacks comparing Trump to Adolf Hitler and Trump voters to fascists....” Why no mention of the same types of attacks by Donald Trump or his supporters? Strada is right to criticize Barack Obama’s guns and religion comment and Hillary Clinton’s basket of deplorables gaffe. I also think the Democratic Party has lost touch with its original constituency, the middle and blue-collar classes. However, Trump’s Thanksgiving message referred to “Radical Left Lunatics.” His accusation that Democrats are trying “to destroy” America was hyperbolic as was his violent talk about Liz Cheney . Her actual offense? Standing up for what she felt was right, political consequences notwithstanding. Add his witty but insulting names like George Slopadopolous instead of Stephanopolous or Gavin Newscum instead of Newsome. RECOMMENDED • cleveland .com A Trump voter’s modest proposal for moving ahead without rancor or finger-pointing: Andrew P. Strada Dec. 1, 2024, 5:22 a.m. Ohio’s $1B private school voucher program - where’s the accountability? Nov. 29, 2024, 2:53 p.m. Face it. Both sides often refuse to admit their respective faults. Bob Sheridan, Lyndhurst

Who are the favorites to win Golden Globes? | Streamed & Screened podcast